PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel

(Reuters) - PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news